{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:16:40Z","timestamp":1792502200195,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000090","name":"US Office of Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"University of California San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201820","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:35:32Z","timestamp":1785195332000},"page":"201820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["i.c.v. delivery of AAV9-synapsin-promoted caveolin-1 attenuates neuromuscular deficits and neuromuscular degeneration in hSOD1G93A mice"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5941-3369","authenticated-orcid":false,"given":"Noriyuki","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Kawahori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinh","family":"Ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A.","family":"Ohgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Kleschevnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-5351","authenticated-orcid":false,"given":"Brian P.","family":"Head","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201820_bib1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/21678421.2024.2358786","article-title":"Prevalence of ALS in all 50 states in the United States, data from the National ALS Registry, 2011-2018","volume":"25","author":"Mehta","year":"2024","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"10.1016\/j.omta.2026.201820_bib2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s00415-019-09652-y","article-title":"Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"267","author":"Xu","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.omta.2026.201820_bib3","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(07)60944-1","article-title":"Amyotrophic lateral sclerosis","volume":"369","author":"Mitchell","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201820_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-075037","article-title":"Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis","volume":"383","author":"Ilieva","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.omta.2026.201820_bib5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Kiernan","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201820_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/bs.irn.2024.04.007","article-title":"Recent advances in the genetics of familial and sporadic ALS","volume":"176","author":"Al-Chalabi","year":"2024","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.omta.2026.201820_bib7","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.neuron.2020.08.022","article-title":"ALS Genetics: Gains, Losses, and Implications for Future Therapies","volume":"108","author":"Kim","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.omta.2026.201820_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201820_bib9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omta.2026.201820_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12916-024-03314-1","article-title":"TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro","volume":"22","author":"Duan","year":"2024","journal-title":"BMC Med."},{"key":"10.1016\/j.omta.2026.201820_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41591-019-0674-1","article-title":"Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS","volume":"26","author":"Bravo-Hernandez","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201820_bib12","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1096\/fj.07-9299com","article-title":"Caveolin-1 expression is essential for N-methyl-D-aspartate receptor-mediated Src and extracellular signal-regulated kinase 1\/2 activation and protection of primary neurons from ischemic cell death","volume":"22","author":"Head","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.omta.2026.201820_bib13","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1113\/JP270590","article-title":"Membrane lipid rafts and neurobiology: age-related changes in membrane lipids and loss of neuronal function","volume":"594","author":"Egawa","year":"2016","journal-title":"J. Physiol."},{"key":"10.1016\/j.omta.2026.201820_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.biopsych.2015.09.020","article-title":"Neuron-Targeted Caveolin-1 Improves Molecular Signaling, Plasticity, and Behavior Dependent on the Hippocampus in Adult and Aged Mice","volume":"81","author":"Mandyam","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.omta.2026.201820_bib15","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1096\/fj.201802652RR","article-title":"Neuron-targeted caveolin-1 improves neuromuscular function and extends survival in SOD1(G93A) mice","volume":"33","author":"Sawada","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.omta.2026.201820_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/alz.71450","article-title":"Systemic delivery of synapsin-promoted caveolin-1 overexpression ameliorates pathological TDP-43-induced cognitive decline and neurodegenerative changes","volume":"22","author":"Wang","year":"2026","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.omta.2026.201820_bib17","doi-asserted-by":"crossref","first-page":"33310","DOI":"10.1074\/jbc.M111.255976","article-title":"Neuron-targeted caveolin-1 protein enhances signaling and promotes arborization of primary neurons","volume":"286","author":"Head","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201820_bib18","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1126\/science.8209258","article-title":"Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation","volume":"264","author":"Gurney","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.omta.2026.201820_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.nbd.2007.07.003","article-title":"Time course of preferential motor unit loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis","volume":"28","author":"Hegedus","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omta.2026.201820_bib20","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.7150\/thno.72614","article-title":"Subpial delivery of adeno-associated virus 9-synapsin-caveolin-1 (AAV9-SynCav1) preserves motor neuron and neuromuscular junction morphology, motor function, delays disease onset, and extends survival in hSOD1G93A mice","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.omta.2026.201820_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omtm.2018.12.001","article-title":"Kinetics and MR-Based Monitoring of AAV9 Vector Delivery into Cerebrospinal Fluid of Nonhuman Primates","volume":"13","author":"Ohno","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201820_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3457","article-title":"Early distribution of(18) F-labeled AAV9 vectors in the cerebrospinal fluid after intracerebroventricular or intracisternal magna infusion in non-human primates","volume":"25","author":"Kumagai","year":"2023","journal-title":"J. Gene Med."},{"key":"10.1016\/j.omta.2026.201820_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201820_bib24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201820_bib25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/hum.2022.163","article-title":"Biodistribution of Adeno-Associated Virus Gene Therapy Following Cerebrospinal Fluid-Directed Administration","volume":"34","author":"Chen","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201820_bib26","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.adm8386","article-title":"An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery","volume":"384","author":"Huang","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.omta.2026.201820_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.32","article-title":"Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model","volume":"1","author":"Huda","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201820_bib28","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ymthe.2019.07.017","article-title":"AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice","volume":"27","author":"Liguore","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201820_bib29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ymthe.2019.11.012","article-title":"A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna","volume":"28","author":"Taghian","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201820_bib30","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1016\/j.ymthe.2024.08.024","article-title":"A minimally invasive endovascular approach to the cerebellopontine angle cistern enables broad CNS biodistribution of scAAV9-CB-GFP","volume":"32","author":"Benatti","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201820_bib31","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1007\/s00415-020-10073-5","article-title":"Motor-evoked potentials in amyotrophic lateral sclerosis: potential implications in detecting subclinical UMN involvement in lower motor neuron phenotype","volume":"267","author":"Zoccolella","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.omta.2026.201820_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70055","article-title":"MEPs and MRI Motor Band Sign as Potential Complementary Markers of Upper Motor Neuron Involvement in Amyotrophic Lateral Sclerosis","volume":"32","author":"Calvi","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.omta.2026.201820_bib33","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/mt.2013.95","article-title":"Mouse gender influences brain transduction by intravascularly administered AAV9","volume":"21","author":"Maguire","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201820_bib34","doi-asserted-by":"crossref","first-page":"12693","DOI":"10.3390\/ijms232012693","article-title":"Sex Difference Leads to Differential Gene Expression Patterns and Therapeutic Efficacy in Mucopolysaccharidosis IVA Murine Model Receiving AAV8 Gene Therapy","volume":"23","author":"Piechnik","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2026.201820_bib35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.chest.2018.06.035","article-title":"Respiratory Failure in Amyotrophic Lateral Sclerosis","volume":"155","author":"Niedermeyer","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.omta.2026.201820_bib36","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1016\/j.jpainsymman.2023.06.029","article-title":"Palliative Care in Amyotrophic Lateral Sclerosis","volume":"66","author":"Mercadante","year":"2023","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.omta.2026.201820_bib37","article-title":"EphrinB2 knockdown in cervical spinal cord preserves diaphragm innervation in a mutant SOD1 mouse model of ALS","author":"Urban","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.omta.2026.201820_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nbd.2015.03.010","article-title":"GLT1 overexpression in SOD1(G93A) mouse cervical spinal cord does not preserve diaphragm function or extend disease","volume":"78","author":"Li","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omta.2026.201820_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115730","article-title":"Enhancer AAVs for targeting spinal motor neurons and descending motor pathways in rodents and macaque","volume":"44","author":"Kussick","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.omta.2026.201820_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.55","article-title":"AAV9-mediated central nervous system-targeted gene delivery via cisterna magna route in mice","volume":"3","author":"Lukashchuk","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201820_bib41","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ydbio.2005.04.017","article-title":"Identification of a conserved 125 base-pair Hb9 enhancer that specifies gene expression to spinal motor neurons","volume":"283","author":"Nakano","year":"2005","journal-title":"Dev. Biol."},{"key":"10.1016\/j.omta.2026.201820_bib42","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2418024121","article-title":"Cis-regulatory elements driving motor neuron-selective viral payload expression within the mammalian spinal cord","volume":"121","author":"Nagy","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201820_bib43","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.7150\/thno.56070","article-title":"R13 preserves motor performance in SOD1(G93A) mice by improving mitochondrial function","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.omta.2026.201820_bib44","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bph.16260","article-title":"Pharmacological inhibition of the integrated stress response accelerates disease progression in an amyotrophic lateral sclerosis mouse model","volume":"181","author":"Marlin","year":"2024","journal-title":"Br. J. Pharmacol."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:14:19Z","timestamp":1789053259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X26001552"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201820","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"i.c.v. delivery of AAV9-synapsin-promoted caveolin-1 attenuates neuromuscular deficits and neuromuscular degeneration in hSOD1G93A mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201820"}}